Global Psoriasis Drugs Market to Exceed $7.3 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Psoriasis drugs markets. The world market for psoriasis drugs is projected to exceed $7.3 billion by the year 2015. The market is expected to witness robust growth, as anti-TNF therapies continue to gain momentum. Enbrel and Humira are expected to drive the psoriasis drugs market through 2015. Nevertheless, factors expected to drive success of topical therapies include emergence of new, improved products in continuation of the existing therapies; introduction of new vehicles for topical drug delivery; and accessibility of Calcipotriol ointment.

Psoriasis Drugs: A Global Strategic Business Report

Psoriasis is one of the most widespread autoimmune diseases and affects more than 2% of the total global population. The disease is characterized by the presence of red, scaly patches known as psoriatic plaques, which are inflamed and are areas of excessive skin production. Psoriasis has no known cause, but is strongly linked to genetics. Psoriasis cannot be cured, but there are several therapies available that can help alleviate symptoms and improve the quality of life of patients.

The United States dominates the world psoriasis drugs market as stated by the new market research report on Psoriasis Drugs market. The US is also the fastest growing regional market for psoriasis therapeutics. Systemic drugs, encompassing conventional systemic drugs and biologics, dominate the global psoriasis drugs market. Of all patients treated with a systemic drug therapy, the number of patients treated with biologics is expected to double in the next six to eight years. Though other treatment options also are available, such as phototherapy, genericized conventional systemic agents and topical agents account for the largest share of volume prescriptions for psoriasis treatment. Taclonex, a vitamin D analog (calcitriol) and anti-inflammatory corticosteroid (betamethasone) combination product, dominates the global market for topical drugs.

Key players profiled in the report include Abbott Laboratories, Amgen Inc., Almirall SA, Astellas Pharma US Inc., Biogen Idec Inc., Eisai Co. Ltd., Galderma Laboratories, Isis Pharmaceuticals Inc., Johnson & Johnson Company, LEO Pharma A/S, Merck & Co. Inc., Novartis AG, Stiefel Laboratories Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Vertex Pharmaceuticals Inc., and Wyeth.

The report titled "Psoriasis Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of psoriasis market, disease prevalence, market trends, market drivers, marketed drugs, systemic drugs, biologics, topical drugs, potential drugs, clinical trials, product introductions/approvals, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Japan, Europe, and Rest of World. The study analyzes market data and analytics in terms of value sales for psoriasis drugs by route of drug administration, including Systemic Drugs, and Topical Drugs

For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Psoriasis_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website